Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VIS649-102: A sequential treatment, phase 1, open-label study to assess the pharmacokinetics, safety and tolerability, and pharmacodynamics of VIS649 solution administered subcutaneously in healthy male and female participants aged 18 to 55 years.

Next Previous
Trial Profile

VIS649-102: A sequential treatment, phase 1, open-label study to assess the pharmacokinetics, safety and tolerability, and pharmacodynamics of VIS649 solution administered subcutaneously in healthy male and female participants aged 18 to 55 years.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sibeprenlimab (Primary)
  • Indications IgA nephropathy
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms VIS649-102

Most Recent Events

  • 21 Jan 2022 Planned number of patients changed from 36 to 48.
  • 21 Jan 2022 Status changed from recruiting to completed.
  • 17 Dec 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top